Top Markets
Coin of the day
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
株式のランク #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
株価
$0.28078542
時価総額
$199.87M
変化(1日)
-0.34%
変化(1年)
-10.19%
TW
取引 TaiGen Biopharmaceuticals Holdings Limited (4157)

カテゴリー

TaiGen Biopharmaceuticals Holdings Limited(4157)の配当利回りの履歴
TaiGen Biopharmaceuticals Holdings Limited(銘柄コード: 4157)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
TaiGen Biopharmaceuticals Holdings Limited(4157)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)